Showing 2511-2520 of 5623 results for "".
- Ocular Therapeutix Submits Supplemental NDA for Dextenza for Treatment of Ocular Itching Associated with Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-submits-supplemental-nda-for-dextenza-for-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis/2478693/Ocular Therapeutix announced the submission of the supplemental new drug application (sNDA) to the FDA for Dextenza (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use. If approved, this sNDA would include the treatment of ocular itching associated with allergic conjunctivitis as an
- Nidek Launches B-scan Denoising Software With Deep Learning to Enhance OCT Retinal Image Qualityhttps://modernod.com/news/nidek-launches-b-scan-denoising-software-with-deep-learning-to-enhance-oct-retinal-image-quality/2478684/Nidek has announced the launch of the B-scan Denoising Software for the Nidek OCT series. This software converts a B-scan retinal OCT image to a high definition image by a denoising technique using deep learnin
- Kubota Vision Provides Update on Kubota Glasses—Wearable Device for Myopia Controlhttps://modernod.com/news/kubota-vision-provides-update-on-kubota-glasses-wearable-device-for-myopia-control/2478680/Kubota Vision announced that the company achieved a milestone by completing a first spectacle-style wearable prototype based on Kubota Glasses technology. Kubota Vision conducted a clinical study in early 2020 with an electronic tabletop optical projection device that embodied Kubota Glass
- Demand, Pay for Travel ICU Nurses Soar as Hospitals Face Staff Crunch Due to COVID-19https://modernod.com/news/demand-pay-for-travel-icu-nurses-soar-as-hospitals-face-staff-crunch-due-to-covid-19/2478681/Staffing crunches caused by COVID-19 created a massive 305% increase in demand for intensive care unit travel nurses from March to November, according to a new report, as
- Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseaseshttps://modernod.com/news/gyroscope-therapeutics-and-the-university-of-pennsylvania-announce-research-agreement-to-develop-gene-therapies-for-serious-eye-diseases/2478679/Gyroscope Therapeutics announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead to permanent vision loss. Gyroscope
- EyeQue to Launch VisionCheck 2 Do-It-Yourself Smartphone Vision Testhttps://modernod.com/news/eyeque-to-launch-visioncheck-2-do-it-yourself-smartphone-vision-test/2478648/EyeQue announced the upcoming launch of EyeQue VisionCheck 2, a refraction device available for consumers to test their own vision and order new glasses from home. VisionCheck 2 is a lightweight optical smartphone attachment and mobile app. The test results are expr
- Foundation Fighting Blindness Appoints Peter Ginsberg as Executive Vice President, Corporate Development, Chief Business Officerhttps://modernod.com/news/foundation-fighting-blindness-appoints-peter-ginsberg-as-executive-vice-president-corporate-development-chief-business-officer/2478647/The Foundation Fighting Blindness announced the appointment of Peter Ginsberg as executive vice president, corporate development, chief business officer. Mr. Ginsberg will oversee the development of financial plans and processes while providing leadership on busines
- NextGen Launches a Dedicated Optometric Workflow in its Fully Integrated Eye Care Platformhttps://modernod.com/news/nextgen-launches-a-dedicated-optometric-workflow-in-its-fully-integrated-eye-care-platform/2478643/NextGen Healthcare announced it has launched a dedicated optometric workflow in its fully integrated eye care platform. This new optometric software solution is part of the NextGen Ophthalmic Suite, which integrates b
- SIFI Appoints Jelle Kleijn to Lead Effort to Deliver First Registered Treatment of Acanthamoeba Keratitishttps://modernod.com/news/sifi-appoints-jelle-kleijn-to-lead-effort-to-deliver-first-registered-treatment-of-acanthamoeba-keratitis/2478631/SIFI has announced the recent appointment of Jelle Kleijn, PhD, as Global Head of Acanthamoeba keratitis. Dr. Kleijn will lead the efforts aimed at developing and making polihexanide monotherapy available to Acanthamoeba keratitis (AK) patients. Given the urgency to effectively treat AK to
- Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies in Ophthalmic Diseaseshttps://modernod.com/news/maze-therapeutics-and-alloy-therapeutics-form-broadwing-bio-to-develop-antibody-therapies-in-ophthalmic-diseases/2478632/Maze Therapeutics and Alloy Therapeutics announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases. Broadwing Bio will advance programs directed to genetically validated ophthalmology targets identified using Maze’s human genetics and